Figure 5.
Rb1cc1 deletion sensitizes BPK mammary tumors to mitochondrial-disrupting agents. BPK cells were plated at a density of 10,000 cells per well in a 96-well format and incubated overnight before treatment with respective drugs for 48 h. Dose response curves for BPK primary cells with Rb1cc1F/+ or rb1cc1F/F alleles treated with (a) chemotherapeutic drugs, (b) targeted therapeutic drugs or (c) mitochondrial-disrupting agents. (Data points represent n = 6, triplicates of 2 independent experiments.) Statistical significance was determined by two-tailed t-test, * denotes p ≤ 0.05, ** denotes p ≤ 0.01 and *** denotes p ≤ 0.001.